Rome, Nov 16. (Adnkronos Health) – “The patient can no longer be considered as the sum of individual organs or individual pathologies. Heart, kidneys, and metabolism are part of a single system, and their state of health is deeply interconnected. This is why today we must increasingly talk about integrated management of the cardio-nephro-metabolic patient.” This was stated by Salvatore Corrao, director of Internal Medicine at Arnas Civico in Palermo, on the sidelines of the clinical-institutional roundtable ‘Integrated management of the cardio-nephro-metabolic patient’, which took place in Palermo, at Palazzo dei Normanni, organized by Summeet with the unconditional contribution of Bayer.
Cardio-nephro-metabolic syndrome (CNMS) today represents one of the main clinical and organizational challenges for the Regional Health Service, due to the close interconnection between cardiovascular diseases, chronic kidney disease, type 2 diabetes mellitus, and obesity. The clinical complexity of these patients requires integrated, multidisciplinary care models oriented towards continuity of care. “Obesity and diabetes,” explained Corrao, “are two particularly evident examples of how relevant this interconnection is. They are extremely widespread conditions in the population and can promote, through different and often concomitant mechanisms, the onset or progression of cardiovascular and renal diseases. Added to this is the role of the liver, which significantly participates in the complex network of metabolic alterations that characterizes these patients. The central point is that we can no longer address these pathologies through separate pathways. The patient presenting with diabetes, obesity, kidney disease, or cardiovascular risk needs a comprehensive assessment of their risk profile and a care pathway built around the individual. This means intervening early, when it is still possible to modify the natural history of the disease, and not necessarily waiting for the appearance of advanced organ damage.”
For Corrao, the clinical, but also organizational, challenge for the National Health Service is “to move from a medicine that primarily intervenes on a single complication to a medicine capable of anticipating risk, early identifying the most vulnerable patients, and accompanying them along a continuous path.”